Predictors of poor seroconversion and adverse events to SARS-CoV-2 mRNA BNT162b2 vaccine in cancer patients on active treatment

PURPOSE: Initial findings in patients with cancer suggest a lower seroconversion to SARS-CoV-2 vaccination possibly related to myelo-immunosuppressive therapies. We conducted a prospective study to assess factors predicting poor seroconversion and adverse events following immunisation (AEFI) to the...

Descripción completa

Detalles Bibliográficos
Autores principales: Buttiron Webber, Tania, Provinciali, Nicoletta, Musso, Marco, Ugolini, Martina, Boitano, Monica, Clavarezza, Matteo, D'Amico, Mauro, Defferrari, Carlotta, Gozza, Alberto, Briata, Irene Maria, Magnani, Monica, Paciolla, Fortuna, Menghini, Nadia, Marcenaro, Emanuela, De Palma, Raffaele, Sacchi, Nicoletta, Innocenti, Leonello, Siri, Giacomo, D'Ecclesiis, Oriana, Cevasco, Isabella, Gandini, Sara, DeCensi, Andrea
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Published by Elsevier Ltd. 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502731/
https://www.ncbi.nlm.nih.gov/pubmed/34742157
http://dx.doi.org/10.1016/j.ejca.2021.09.030

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8502731/
https://www.ncbi.nlm.nih.gov/pubmed/34742157
http://dx.doi.org/10.1016/j.ejca.2021.09.030

Ejemplares similares